Ryoncil

News
A new approach to COVID-19 treatment

Mesoblast pummelled as Novartis exits COVID deal

Novartis as opted out of a collaboration with Mesoblast to develop its stem cell-based therapy remestemcel-L as a treatment for COVID-19, prompting a slump in the biotech's share price.